Supporting Information
Additional supporting information may be found online in the Supporting
Information section at the end of article.
Appendix S1. Local recurrence free survival of all investigated
patients.
Appendix S2. Metastasis recurrence free survival of all
investigated patients.
Appendix S3. Disease free survival of all investigated
patients.
Appendix S4. Cancer special survival of all investigated
patients.
References
1. Chemoradiotherapy for Cervical
Cancer Meta-analysis C. Reducing uncertainties about the effects of
chemoradiotherapy for cervical cancer: individual patient data
meta-analysis. The Cochrane database of systematic reviews. 2010 Jan
20(1):CD008285.
2. Green J, Kirwan J, Tierney J, Vale
C, Symonds P, Fresco L, et al. Concomitant chemotherapy and radiation
therapy for cancer of the uterine cervix. The Cochrane database of
systematic reviews. 2005 Jul 20(3):CD002225.
3. Green JA, Kirwan JM, Tierney JF,
Symonds P, Fresco L, Collingwood M, et al. Survival and recurrence after
concomitant chemotherapy and radiotherapy for cancer of the uterine
cervix: a systematic review and meta-analysis. Lancet. 2001 Sep
8;358(9284):781-6.
4. Rose PG, Bundy BN, Watkins EB,
Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based
radiotherapy and chemotherapy for locally advanced cervical cancer. The
New England journal of medicine. 1999 Apr 15;340(15):1144-53.
5. Nakano T, Kato S, Ohno T, Tsujii H,
Sato S, Fukuhisa K, et al. Long-term results of high-dose rate
intracavitary brachytherapy for squamous cell carcinoma of the uterine
cervix. Cancer. 2005 Jan 1;103(1):92-101.
6. Nag S, Cardenes H, Chang S, Das IJ,
Erickson B, Ibbott GS, et al. Proposed guidelines for image-based
intracavitary brachytherapy for cervical carcinoma: report from
Image-Guided Brachytherapy Working Group. International journal of
radiation oncology, biology, physics. 2004 Nov 15;60(4):1160-72.
7. Potter R, Tanderup K, Schmid MP,
Jurgenliemk-Schulz I, Haie-Meder C, Fokdal LU, et al. MRI-guided
adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I):
a multicentre prospective cohort study. Lancet Oncol. 2021
Apr;22(4):538-47.
8. Potter R, Georg P, Dimopoulos JC,
Grimm M, Berger D, Nesvacil N, et al. Clinical outcome of protocol based
image (MRI) guided adaptive brachytherapy combined with 3D conformal
radiotherapy with or without chemotherapy in patients with locally
advanced cervical cancer. Radiother Oncol. 2011 Jul;100(1):116-23.
9. Fallon J, Park SJ, Yang L,
Veruttipong D, Zhang M, Van T, et al. Long term results from a
prospective database on high dose rate (HDR) interstitial brachytherapy
for primary cervical carcinoma. Gynecol Oncol. 2016 Oct 29.
10. Tan LT, Potter R, Sturdza A,
Fokdal L, Haie-Meder C, Schmid M, et al. Change in Patterns of Failure
After Image-Guided Brachytherapy for Cervical Cancer: Analysis From the
RetroEMBRACE Study. International journal of radiation oncology,
biology, physics. 2019 Jul 15;104(4):895-902.
11. Han K, Milosevic M, Fyles A,
Pintilie M, Viswanathan AN. Trends in the utilization of brachytherapy
in cervical cancer in the United States. International journal of
radiation oncology, biology, physics. 2013 Sep 1;87(1):111-9.
12. Gill BS, Lin JF, Krivak TC,
Sukumvanich P, Laskey RA, Ross MS, et al. National Cancer Data Base
analysis of radiation therapy consolidation modality for cervical
cancer: the impact of new technological advancements. International
journal of radiation oncology, biology, physics. 2014 Dec
1;90(5):1083-90.
13. Hanks GE, Herring DF, Kramer S.
Patterns of care outcome studies. Results of the national practice in
cancer of the cervix. Cancer. 1983 Mar 1;51(5):959-67.
14. Coia L, Won M, Lanciano R,
Marcial VA, Martz K, Hanks G. The Patterns of Care Outcome Study for
cancer of the uterine cervix. Results of the Second National Practice
Survey. Cancer. 1990 Dec 15;66(12):2451-6.
15. Tod M, Meredith WJ. Treatment of
cancer of the cervix uteri, a revised Manchester method. The British
journal of radiology. 1953 May;26(305):252-7.
16. Kim RY, Pareek P.
Radiography-based treatment planning compared with computed tomography
(CT)-based treatment planning for intracavitary brachytherapy in cancer
of the cervix: analysis of dose-volume histograms. Brachytherapy.
2003;2(4):200-6.
17. Fellner C, Potter R, Knocke TH,
Wambersie A. Comparison of radiography- and computed tomography-based
treatment planning in cervix cancer in brachytherapy with specific
attention to some quality assurance aspects. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology.
2001 Jan;58(1):53-62.
18. Murakami N, Kasamatsu T, Wakita
A, Nakamura S, Okamoto H, Inaba K, et al. CT based three dimensional
dose-volume evaluations for high-dose rate intracavitary brachytherapy
for cervical cancer. BMC cancer. 2014 Jun 17;14:447.
19. Charra-Brunaud C, Harter V,
Delannes M, Haie-Meder C, Quetin P, Kerr C, et al. Impact of 3D
image-based PDR brachytherapy on outcome of patients treated for cervix
carcinoma in France: results of the French STIC prospective study.
Radiotherapy and oncology : journal of the European Society for
Therapeutic Radiology and Oncology. 2012 Jun;103(3):305-13.
20. Fokdal L, Sturdza A, Mazeron R,
Haie-Meder C, Tan LT, Gillham C, et al. Image guided adaptive
brachytherapy with combined intracavitary and interstitial technique
improves the therapeutic ratio in locally advanced cervical cancer:
Analysis from the retroEMBRACE study. Radiother Oncol. 2016
Sep;120(3):434-40.
21. Nomden CN, de Leeuw AA, Moerland
MA, Roesink JM, Tersteeg RJ, Jurgenliemk-Schulz IM. Clinical use of the
Utrecht applicator for combined intracavitary/interstitial brachytherapy
treatment in locally advanced cervical cancer. Int J Radiat Oncol Biol
Phys. 2012 Mar 15;82(4):1424-30.
22. Beriwal S, Rwigema JC, Higgins E,
Kim H, Houser C, Sukumvanich P, et al. Three-dimensional image-based
high-dose-rate interstitial brachytherapy for vaginal cancer.
Brachytherapy. 2012 May-Jun;11(3):176-80.
23. Duan J, Kim RY, Elassal S, Lin
HY, Shen S. Conventional high-dose-rate brachytherapy with concomitant
complementary IMRT boost: a novel approach for improving cervical tumor
dose coverage. Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):765-71.
24. Assenholt MS, Vestergaard A,
Kallehauge JF, Mohamed S, Nielsen SK, Petersen JB, et al. Proof of
principle: Applicator-guided stereotactic IMRT boost in combination with
3D MRI-based brachytherapy in locally advanced cervical cancer.
Brachytherapy. 2014 Jul-Aug;13(4):361-8.
25. Klepczyk L, Shen S, Duan J, Kim
RY. Image-Based Intracavitary Brachytherapy with Concurrent
Applicator-Guided IMRT Boost for Cervical Cancer. Brachytherapy.
2013;12(Suppl 1):S56-S7.
26. Haie-Meder C, Potter R, Van
Limbergen E, Briot E, De Brabandere M, Dimopoulos J, et al.
Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I):
concepts and terms in 3D image based 3D treatment planning in cervix
cancer brachytherapy with emphasis on MRI assessment of GTV and CTV.
Radiotherapy and oncology : journal of the European Society for
Therapeutic Radiology and Oncology. 2005 Mar;74(3):235-45.
27. Potter R, Haie-Meder C, Van
Limbergen E, Barillot I, De Brabandere M, Dimopoulos J, et al.
Recommendations from gynaecological (GYN) GEC ESTRO working group (II):
concepts and terms in 3D image-based treatment planning in cervix cancer
brachytherapy-3D dose volume parameters and aspects of 3D image-based
anatomy, radiation physics, radiobiology. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology.
2006 Jan;78(1):67-77.
28. Vordermark D. Radiotherapy of
Cervical Cancer. Oncol Res Treat. 2016;39(9):516-20.
29. Albuquerque K TV, Lea J, Ahn C,
Richardson D, Miller D, Timmerman R. A Phase II Trial of Stereotactic
Ablative Radiation Therapy as a Boost for Locally Advanced Cervical
Cancer. Int J Radiat Oncol Biol Phys. 2020;106((3)):464-71. .
30. Alektiar KM. Can
intensity-modulated radiation therapy replace brachytherapy in the
management of cervical cancer? Point. Brachytherapy. 2002;1(4):191-2.
31. Dobelbower MC, Shen S, Popple R,
Kim RY. Dosimetric comparison of IMRT to HDR intracavitary brachytherapy
for cervical cancer. Brachytherapy. 2007;6(2).
32. Kilic S, Cracchiolo B, Mahmoud O.
Non-brachytherapy alternative in cervical cancer radiotherapy: Why not?
Applied radiation Oncology. 2015;4:11-7.
33.www.embracestudy.dk
34. Potter R, Tanderup K, Kirisits C,
de Leeuw A, Kirchheiner K, Nout R, et al. The EMBRACE II study: The
outcome and prospect of two decades of evolution within the GEC-ESTRO
GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol.
2018 Feb;9:48-60.
35. Assenholt MS, Petersen JB,
Nielsen SK, Lindegaard JC, Tanderup K. A dose planning study on
applicator guided stereotactic IMRT boost in combination with 3D MRI
based brachytherapy in locally advanced cervical cancer. Acta Oncol.
2008;47(7):1337-43.
36. Yin G, Wang P, Lang J, Tian Y,
Luo Y, Fan Z, et al. Dosimetric study for cervix carcinoma treatment
using intensity modulated radiation therapy (IMRT) compensation based on
3D intracavitary brachytherapy technique. Journal of contemporary
brachytherapy. 2016 Jun;8(3):221-32.
37. Wang X, Li J, Wang P, Yuan K, Yin
G, Wan B. Image guided radiation therapy boost in combination with
high-dose-rate intracavitary brachytherapy for the treatment of cervical
cancer. J Contemp Brachytherapy. 2016 Apr;8(2):122-7.
38. Kirisits C, Potter R, Lang S,
Dimopoulos J, Wachter-Gerstner N, Georg D. Dose and volume parameters
for MRI-based treatment planning in intracavitary brachytherapy for
cervical cancer. Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):901-11.
39. Tanderup K, Potter R, Lindegaard
JC, Berger D, Wambersie A, Kirisits C. PTV margins should not be used to
compensate for uncertainties in 3D image guided intracavitary
brachytherapy. Radiother Oncol. 2010 Dec;97(3):495-500.
40. Jurgenliemk-Schulz IM, Tersteeg
RJ, Roesink JM, Bijmolt S, Nomden CN, Moerland MA, et al. MRI-guided
treatment-planning optimisation in intracavitary or combined
intracavitary/interstitial PDR brachytherapy using tandem ovoid
applicators in locally advanced cervical cancer. Radiother Oncol. 2009
Nov;93(2):322-30.
41. Yoshida K, Yamazaki H, Kotsuma T,
Takenaka T, Ueda MM, Miyake S, et al. Simulation analysis of optimized
brachytherapy for uterine cervical cancer: Can we select the best
brachytherapy modality depending on tumor size? Brachytherapy. 2016
Jan-Feb;15(1):57-64.
42. Dimopoulos JC, Lang S, Kirisits
C, Fidarova EF, Berger D, Georg P, et al. Dose-volume histogram
parameters and local tumor control in magnetic resonance image-guided
cervical cancer brachytherapy. International journal of radiation
oncology, biology, physics. 2009 Sep 1;75(1):56-63.
43. Lindegaard JC, Fokdal LU, Nielsen
SK, Juul-Christensen J, Tanderup K. MRI-guided adaptive radiotherapy in
locally advanced cervical cancer from a Nordic perspective. Acta Oncol.
2013 Oct;52(7):1510-9.
44. Potter R, Dimopoulos J, Georg P,
Lang S, Waldhausl C, Wachter-Gerstner N, et al. Clinical impact of MRI
assisted dose volume adaptation and dose escalation in brachytherapy of
locally advanced cervix cancer. Radiother Oncol. 2007 May;83(2):148-55.
45. Mazeron R, Fokdal LU, Kirchheiner
K, Georg P, Jastaniyah N, Segedin B, et al. Dose-volume effect
relationships for late rectal morbidity in patients treated with
chemoradiation and MRI-guided adaptive brachytherapy for locally
advanced cervical cancer: Results from the prospective multicenter
EMBRACE study. Radiother Oncol. 2016 Sep;120(3):412-9.
46. Fokdal L, Potter R, Kirchheiner
K, Lindegaard JC, Jensen NBK, Kirisits C, et al. Physician assessed and
patient reported urinary morbidity after radio-chemotherapy and image
guided adaptive brachytherapy for locally advanced cervical cancer.
Radiother Oncol. 2018 Jun;127(3):423-30.